Home » Stocks » WVE

Wave Life Sciences Ltd. (WVE)

Stock Price: $5.84 USD -0.62 (-9.60%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Pre-market: $5.62 -0.22 (-3.77%) Jul 26, 8:33 AM
Market Cap 293.83M
Revenue (ttm) 15.92M
Net Income (ttm) -144.88M
Shares Out 50.31M
EPS (ttm) -3.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $5.84
Previous Close $6.46
Change ($) -0.62
Change (%) -9.60%
Day's Open 6.48
Day's Range 5.79 - 6.49
Day's Volume 279,513
52-Week Range 4.82 - 19.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin defic...

1 month ago - Benzinga

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...

1 month ago - GlobeNewsWire

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 37.68% over the past year to ($0.86), which missed the estimate ...

2 months ago - Benzinga

Clinical trials underway with next-generation candidates incorporating PN chemistry

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...

2 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AFMD, CMRX, EPZM, SEEL
3 months ago - 24/7 Wall Street

No one ever said drug development was easy.

3 months ago - The Motley Fool

Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happ...

3 months ago - Benzinga

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101

3 months ago - GlobeNewsWire

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...

4 months ago - GlobeNewsWire

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 64.24% year over year to ($0.59), which beat the estimat...

4 months ago - Benzinga

Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

5 months ago - GlobeNewsWire

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

5 months ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021

8 months ago - GlobeNewsWire

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

10 months ago - GlobeNewsWire

Investors liked an analyst's upgrade of the biotech stock.

10 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

10 months ago - GlobeNewsWire

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, MRNS, NVUS, PTH ...
10 months ago - Zacks Investment Research

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

10 months ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021

11 months ago - GlobeNewsWire

Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD

11 months ago - GlobeNewsWire

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

11 months ago - GlobeNewsWire

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Newly created position will focus on translating advancements from PRISM platform into new therapeutic candidates Newly created position will focus on translating advancements from PRISM platform into n...

1 year ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.

1 year ago - Benzinga

Data from both PRECISION-HD clinical trials expected in 2H 2020

1 year ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Dr.

1 year ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About WVE

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials f... [Read more...]

Industry
Biotechnology
IPO Date
Nov 11, 2015
CEO
Paul Bolno
Employees
217
Stock Exchange
NASDAQ
Ticker Symbol
WVE
Full Company Profile

Financial Performance

In 2020, WVE's revenue was $20.08 million, an increase of 25.61% compared to the previous year's $15.98 million. Losses were -$149.91 million, -22.58% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 9.14, which is an increase of 56.51% from the latest price.

Price Target
$9.14
(56.51% upside)
Analyst Consensus: Buy